With Two New Deals, Versant Ventures Enlists More Pharma Partners To Share Biotech Risk
This article was originally published in The Pink Sheet Daily
Executive Summary
Versant is betting a sizable amount of its portfolio on drug assets, instead of full-blown companies, with single buyers holding options to acquire each one.